Compare Celsius Holdings, Inc. (CELH) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Celsius Holdings, Inc. vs TransMedics Group Inc — how do they compare? Celsius Holdings, Inc. trades at $27.18 (market cap $7.11B), while TransMedics Group Inc trades at $86.65 (market cap $3.10B). The key difference: Celsius Holdings, Inc. is far larger — about 2.3× TransMedics Group Inc's market cap, and TransMedics Group Inc is trading nearer its 52-week high, Celsius Holdings, Inc. nearer its low. Which is the better fit depends on your goals.
| CELH | TMDX | |
|---|---|---|
Market Cap | $7.11B | $3.10B |
Sector | Consumer Staples | Technology |
52-Week High | $64.86 | $150.42 |
52-Week Low | $23.77 | $61.99 |
Enterprise Value | $8.90B | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CELH trades at $27.21, down 2.02% on the day, with technical indicators signaling a bearish trend. The company reported Q2 2026 earnings of $0.36 per share, missing estimates of $0.4139, while revenue grew 11% year-over-year. Recent news highlights leadership changes and an ongoing shareholder investigation. The stock faces pressure from slowing core-brand growth but benefits from strong analyst support and a partnership with PepsiCo.
Outlook: High growth potential via international expansion and PepsiCo distribution, but execution risks and margin pressures persist. Risks include competitive threats and delayed growth projections. Analyst consensus is strongly bullish with a $44.08 price target, suggesting significant upside if operational challenges are overcome.
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Celsius Holdings, Inc.
Celsius Holdings Inc engages in the development, marketing, sale, and distribution of functional calorie-burning beverages. It offers flavors including cola, orange, wild berry and lemon iced tea and non-carbonated flavors such as Raspberry Acai Green Tea and Peach Mango Green Tea under the Celsius brand name. The company distributes its products through direct-store-delivery distributors, as well as directly to retailers across various retail segments, including supermarkets, convenience stores, drug stores, nutritional stores, mass merchants, health clubs, spas, gyms, military, and e-commerce websites.
Read more on CELH →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
